SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) shares saw strong trading volume on Tuesday . 1,659,246 shares traded hands during mid-day trading, an increase of 92% from the previous session’s volume of 866,356 shares.The stock last traded at $10.29 and had previously closed at $10.38.

The stock has a market cap of $513.87 million and a P/E ratio of 13.89. The firm’s 50-day moving average is $10.84 and its 200-day moving average is $11.71.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 EPS for the quarter. The firm earned $39 million during the quarter, compared to analyst estimates of $37.90 million. Equities research analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.

In other news, Director Nancy T. Chang sold 25,040 shares of the firm’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $10.30, for a total value of $257,912.00. Following the completion of the sale, the director now owns 29,019 shares in the company, valued at approximately $298,895.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the firm’s stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $10.62, for a total transaction of $82,857.24. Following the completion of the sale, the chief financial officer now owns 25,000 shares of the company’s stock, valued at approximately $265,500. The disclosure for this sale can be found here.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.